Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer.

Eric Van Cutsem,Rona Yaeger,Jean-Pierre Delord,Josep Tabernero,Lillian L Siu,Michel Ducreux,Salvatore Siena,Elena Elez, Stefan Kasper,Thomas Zander,Neeltje Steeghs,Danielle Murphy,Michelle Edwards,Zev A Wainberg

The oncologist（2023）

引用 0|浏览46

暂无评分

摘要

The combination of binimetinib and panitumumab had substantial toxicity and limited clinical activity for patients with mutant or WT RAS mCRC, independent of EGFRi treatment history (Trial registration: NCT01927341).

查看译文

关键词

binimetinib, panitumumab, colorectal cancer, RAS mutation, RAS wild type

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要